IL105883A - Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them - Google Patents

Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them

Info

Publication number
IL105883A
IL105883A IL10588393A IL10588393A IL105883A IL 105883 A IL105883 A IL 105883A IL 10588393 A IL10588393 A IL 10588393A IL 10588393 A IL10588393 A IL 10588393A IL 105883 A IL105883 A IL 105883A
Authority
IL
Israel
Prior art keywords
glycosylation
glycosylated
devoid
positions
plasminogen activator
Prior art date
Application number
IL10588393A
Other languages
English (en)
Other versions
IL105883A0 (en
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of IL105883A0 publication Critical patent/IL105883A0/xx
Publication of IL105883A publication Critical patent/IL105883A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL10588393A 1992-06-03 1993-06-02 Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them IL105883A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89421392A 1992-06-03 1992-06-03

Publications (2)

Publication Number Publication Date
IL105883A0 IL105883A0 (en) 1993-10-20
IL105883A true IL105883A (en) 2003-04-10

Family

ID=25402765

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10588393A IL105883A (en) 1992-06-03 1993-06-02 Tissue plasminogen activator glycosylation variants, glycosylated at any one of positions 103 to 105 and devoid of glycosylation at position 117, with improved therapeutic properties, method of preparing and compositions comprising them

Country Status (19)

Country Link
US (1) US5612029A (fr)
EP (2) EP0786257B1 (fr)
JP (1) JP3559559B2 (fr)
AT (2) ATE246000T1 (fr)
AU (1) AU664469B2 (fr)
CA (1) CA2129660C (fr)
DE (3) DE10199044I2 (fr)
DK (2) DK0786257T3 (fr)
EE (1) EE03128B1 (fr)
ES (2) ES2203668T3 (fr)
FI (1) FI117940B (fr)
GE (1) GEP20012448B (fr)
GR (1) GR3024806T3 (fr)
IL (1) IL105883A (fr)
LU (1) LU90800I2 (fr)
NL (1) NL300050I2 (fr)
NZ (1) NZ253556A (fr)
PT (1) PT786257E (fr)
WO (1) WO1993024635A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110721A (en) * 1993-11-12 2000-08-29 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5510330A (en) † 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
DE4423574A1 (de) * 1994-07-05 1996-01-11 Boehringer Mannheim Gmbh Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
WO1999023115A1 (fr) * 1997-10-31 1999-05-14 Eli Lilly And Company Analogues de la proteine de l'obesite glycosylee
US6242473B1 (en) 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
ES2200973T3 (es) 1999-11-04 2004-03-16 Genentech, Inc. Ensayo.
US20030036181A1 (en) * 2000-06-30 2003-02-20 Okkels Jens Sigurd Peptide extended glycosylated polypeptides
NZ532074A (en) * 2001-11-06 2006-02-24 Maxim Pharm Inc Compositions for the treatment of infectious diseases
US20030206906A1 (en) * 2001-11-26 2003-11-06 Genentech, Inc. Catheter composition and uses thereof
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060104969A1 (en) * 2004-08-16 2006-05-18 Massachusetts Institute Of Technology Compositions and methods for enhancing structural and functional nervous system reorganization and recovery
BRPI0610958A2 (pt) * 2005-06-02 2010-08-03 Avestha Gengraine Tech Pvt Ltd método para produzir uma forma obtida por bioengenharia do ativador de plasminogênio tecidual
WO2007030652A2 (fr) * 2005-09-08 2007-03-15 University Of Virginia Patent Foundation Methodes et compositions pour cultiver des cellules souches adipeuses
US20080069857A1 (en) * 2006-04-12 2008-03-20 Yoon Yeo Compositions And Methods For Inhibiting Adhesions
US8969295B2 (en) * 2006-04-14 2015-03-03 Massachusetts Institute Of Technology Identifying and modulating molecular pathways that mediate nervous system plasticity
TWI439282B (zh) 2006-08-29 2014-06-01 Genentech Inc 以血栓溶解劑治療中風之方法
AU2007320031B2 (en) * 2006-10-06 2013-05-02 University Of Virginia Patent Foundation Methods and compositions useful for diabetic wound healing
WO2008070353A2 (fr) 2006-11-07 2008-06-12 Genentech, Inc. Utilisations de variant d'activateur du plasminogène tissulaire
KR100834561B1 (ko) 2006-12-08 2008-06-02 가톨릭대학교 산학협력단 크링글 도메인 1 및 2로 이루어진 비-글리코실화 재조합단백질, 그 제조 방법 및 이를 포함하는 조성물
EP2289542A1 (fr) 2009-08-31 2011-03-02 PAION Deutschland GmbH Traitement des troubles neurologiques ou neuro-dégénératifs
EP2289541A1 (fr) 2009-08-31 2011-03-02 PAION Deutschland GmbH Traitement des troubles neurologiques ou neuro-dégénératifs
US20130122076A1 (en) * 2011-11-11 2013-05-16 Mathew Gelfand Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
WO2014006613A2 (fr) * 2012-07-05 2014-01-09 Hadasit Medical Research Services & Development Limited Mutants de l'activateur du plasminogène à titre d'agents anti-fibrinolytiques
EP2928480B1 (fr) 2012-12-05 2019-09-25 National Jewish Health Traitement d'une obstruction des voies aériennes par des moules bronchiques
CN103159860B (zh) * 2013-04-07 2014-09-24 旭华（上海）生物研发中心有限公司 重组组织型纤溶酶原激活剂及其制备方法与用途
US10220008B2 (en) 2013-08-14 2019-03-05 Stc.Unm Treatment and prevention of stroke and other neurological disorders
CN107073292B (zh) 2014-11-03 2021-07-02 溶栓科学有限责任公司 用于安全和有效的溶栓的方法和组合物
KR102633644B1 (ko) 2017-02-03 2024-02-05 액티코어 바이오테크 항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
WO2018210860A1 (fr) 2017-05-16 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'un accident vasculaire ischémique cérébral aigu
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
EP3806833A1 (fr) 2018-06-15 2021-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de pi3kc2b pour la préservation de l'intégrité d'une barrière cellulaire de l'endothélium vasculaire
WO2021148439A1 (fr) 2020-01-21 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de stimulation de la fonction cérébrovasculaire
EP4161579A1 (fr) 2020-06-09 2023-04-12 Institut National de la Santé et de la Recherche Médicale (INSERM) Particules de polysaccharide fonctionnalisées avec du fucoïdane avec t-pa pour un traitement thrombolytique ciblé
WO2023156683A1 (fr) 2022-02-21 2023-08-24 Acticor Biotech Traitement de maladies cardiovasculaires au moyen d'anticorps anti-gpvi humaine
WO2024229429A1 (fr) 2023-05-04 2024-11-07 Genentech, Inc. Utilisation de tenectéplase pour traitement de patients ayant subi un accident vasculaire cérébral tardif
CN122094706A (zh) * 2023-09-19 2026-05-26 纽约州立大学研究基金会 截短型组织纤溶酶原激活物蛋白及其用途
CN117327682A (zh) * 2023-10-07 2024-01-02 福州大学 一种兼顾高效性与安全性的新型溶栓剂的设计及其应用
EP4556492A1 (fr) 2023-11-14 2025-05-21 Acticor Biotech Traitement de maladies cardiovasculaires à l'aide d'anticorps anti-gpvi humain dans des sous-populations de sujets

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NL8003402A (nl) 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
IL68561A (en) 1982-05-05 1991-01-31 Genentech Inc Preparation of polypeptide with human tissue plasminogen activator function,processes for making it,and dna and transformed cell intermediates thereof
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
EP0125269A1 (fr) * 1982-11-11 1984-11-21 Beecham Group Plc Composes pharmaceutiquement actifs
EP0112122B1 (fr) * 1982-12-14 1991-08-28 South African Inventions Development Corporation Activateur de plasminogène
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4753879A (en) * 1984-08-27 1988-06-28 Biogen N.V. Modified tissue plasminogen activators
ES8702945A1 (es) * 1984-10-01 1987-01-16 Integrated Genetics Inc Un metodo de producir activador de plasminogeno de tejido uterino humano
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0201153A3 (fr) * 1985-02-09 1987-10-07 Beecham Group Plc Enzyme modifié et son procédé de préparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DK149786A (da) * 1985-04-04 1986-10-04 Beecham Group Plc Proteolytisk enzym
DE3613390C2 (de) * 1985-04-22 2001-10-11 Genentech Inc Einkettige Human-Gewebeplasminogen-Aktivator (t-PA)-Mutanten, kodierende DNA, Expressionsvektor, Mikroorganismus, Zellkultur und pharmazeutische Zusammensetzung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
ATE83153T1 (de) * 1985-09-10 1992-12-15 Eisai Co Ltd Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung.
GB8528321D0 (en) * 1985-11-18 1985-12-24 Ciba Geigy Ag Modified fibrinolytic agents
EP0231624B1 (fr) * 1985-12-20 1993-01-27 The Upjohn Company Analogues de l'activateur de plasminogène de tissu
DE3684680D1 (de) 1985-12-23 1992-05-07 Chiron Corp Peptidplasminogenaktivatoren.
DK43387A (da) * 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
WO1987004722A1 (fr) * 1986-01-31 1987-08-13 Genetics Institute, Inc. Nouvelles proteines thrombolytiques
IE81073B1 (en) 1986-03-18 2000-01-12 Genentech Inc Modified human tissue-type plasminogen activator and its preparation
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
AU7090887A (en) 1986-04-02 1987-10-08 Beecham Group Plc Plasminogen activators modified in first kringle domain
PT84589B (en) * 1986-04-02 1989-05-09 Beecham Group Plc Process for preparing a fibrinolytic enzyme
AU7090687A (en) 1986-04-02 1987-10-08 Beecham Group Plc Modified tissue-type plasminogen activators
DE3643158A1 (de) * 1986-04-21 1987-11-19 Boehringer Mannheim Gmbh Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung
JPH0761266B2 (ja) * 1986-07-03 1995-07-05 株式会社ミドリ十字 変異ヒトプロウロキナ−ゼ
DK345087A (da) * 1986-07-11 1988-01-12 Novo Industri As Modificeret vaevsplasminogenaktivator
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
EP0266032A1 (fr) * 1986-08-29 1988-05-04 Beecham Group Plc Enzyme fibrinolytique modifiée
WO1988005081A2 (fr) * 1986-12-30 1988-07-14 Cetus Corporation Nouveaux activateurs du plasminogene
GB8705377D0 (en) * 1987-03-07 1987-04-08 Beecham Group Plc Compounds
DK275788A (da) * 1987-05-22 1989-02-03 Zymogenetics Inc Fibrinolytiske proteiner
ZA883958B (en) * 1987-06-04 1989-07-26 Zymogenetics Inc Mutant t-pa with ringle replacement
IE67036B1 (en) * 1987-06-04 1996-05-15 Zymogenetics Inc Tissue plasminogen activator analogs having modified growth factor domains
SE8702562L (sv) * 1987-06-18 1988-12-19 Kabigen Ab Nya fibrinolytiska enzymer
WO1988010119A1 (fr) * 1987-06-22 1988-12-29 Genetics Institute, Inc. Nouvelles proteines thrombolytiques
US4935237A (en) 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
WO1989000197A1 (fr) * 1987-06-30 1989-01-12 Genentech, Inc. Procedes ameliores permettant le traitement de maladies vasculaires
AU2081788A (en) * 1987-07-06 1989-01-30 Genetics Institute Inc. Novel thrombolytic proteins
AU1893988A (en) * 1987-07-13 1989-01-19 Collaborative Research Inc. Nonglycosylated plasminogen activator and method of preparation
DK468388A (da) 1987-08-21 1989-02-22 Wellcome Found Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset
IL88247A0 (en) 1987-11-06 1989-06-30 Genentech Inc Novel human tissue-type plasminogen activator variant
US5225540A (en) 1988-04-26 1993-07-06 Du Pont Merck Pharmaceutical Company Monoclonal antibodies to tissue plasminogen activator (t-pa) which prolong its functional half-life
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
IL90146A (en) 1988-05-20 1994-10-07 Genentech Inc Glycosylation derivatives of tissue plasminogen activator
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
GB8815135D0 (en) * 1988-06-24 1988-08-03 British Bio Technology Proteins & nucleic acids
DK395288D0 (da) * 1988-07-15 1988-07-15 Novo Industri As Proteiner
US5108901A (en) * 1988-09-02 1992-04-28 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5258180A (en) * 1988-09-02 1993-11-02 Genetech, Inc. Tissue plasminogen activator having fibrin specific properties and deletion of amino acids 466-970, compositions and methods of treatment
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
WO1990003430A1 (fr) 1988-09-23 1990-04-05 Cetus Corporation Milieu de culture de cellules pour l'amelioration de la croissance des cellules, de la longivite de la culture et de l'expression du produit
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1990010649A1 (fr) * 1989-03-06 1990-09-20 The Board Of Regents Of The University Of Texas System Proteases de la superfamille de la chymotrypsine resistantes a la serine, notamment resistantes a pai-1 et a +-pa, mutants inhibiteurs complementaires; compositions; genes; expression
EP0394538B1 (fr) 1989-04-28 1996-10-16 Rhein Biotech Gesellschaft Für Neue Biotechnologische Prozesse Und Produkte Mbh Cellules de levure du genre schwanniomyces
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5087572A (en) 1989-12-01 1992-02-11 Genentech, Inc. Dna encoding human plasminogen modified at the cleavage site
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5246850A (en) * 1990-07-31 1993-09-21 Genentech, Inc. DNA molecules encoding human tissue plasminogen activator variants with decreased clearance, vectors, and host cells
DE69113049T2 (de) 1990-07-31 1996-04-04 Genentech, Inc., South San Francisco, Calif. Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants

Also Published As

Publication number Publication date
NL300050I2 (nl) 2001-11-01
JP3559559B2 (ja) 2004-09-02
ATE246000T1 (de) 2003-08-15
NL300050I1 (nl) 2001-10-01
IL105883A0 (en) 1993-10-20
EE03128B1 (et) 1998-10-15
AU664469B2 (en) 1995-11-16
HK1001190A1 (en) 1998-05-29
US5612029A (en) 1997-03-18
DE10199044I2 (de) 2006-02-09
CA2129660A1 (fr) 1993-12-09
ES2203668T3 (es) 2004-04-16
NZ253556A (en) 1995-11-27
EP0786257B1 (fr) 2003-07-30
LU90800I2 (fr) 2001-10-08
JPH07507448A (ja) 1995-08-24
HK1000449A1 (en) 2004-03-05
FI943632L (fi) 1994-10-04
DE10199044I1 (de) 2002-02-21
DE69312493T2 (de) 1998-01-15
DE69333127T2 (de) 2004-05-06
EP0643772A1 (fr) 1995-03-22
AU4397393A (en) 1993-12-30
WO1993024635A1 (fr) 1993-12-09
FI117940B (fi) 2007-04-30
PT786257E (pt) 2003-12-31
DK0643772T3 (da) 1998-02-02
GEP20012448B (en) 2001-05-25
DE69312493D1 (de) 1997-09-04
ATE155816T1 (de) 1997-08-15
DE69333127D1 (de) 2003-09-04
ES2107041T3 (es) 1997-11-16
EP0786257A1 (fr) 1997-07-30
CA2129660C (fr) 2005-06-28
FI943632A0 (fi) 1994-08-04
DK0786257T3 (da) 2003-10-06
GR3024806T3 (en) 1998-01-30
EP0643772B1 (fr) 1997-07-23

Similar Documents

Publication Publication Date Title
IL105883A0 (en) Tissue plasminogen activator glycosylation variants with improved therapeutic properties
IL80659A0 (en) Modified tissue plasminogen activators,their preparation and pharmaceutical compositions containing them
BE2013C033I2 (fr)
GR3023329T3 (en) Plasma and recombinant protein formulations in low ionic strength media
IL89500A0 (en) Human tissue plasminogen activator variants and processes
EP0776337A4 (fr) Facteur 11 de differentiation de croissance
GR3019328T3 (en) Vampire bat salivary Plasminogen activator vPA-alpha 1
HU912739D0 (en) Stabilization of glycozylized tissue plasminogene activator (t-pa)
DE59005128D1 (de) t-PA pro STABILISIERUNG.
GR3005408T3 (fr)
AU7696087A (en) Recombinant human tissue plasminogen activator composition
IE871856L (en) "modified tissue plasminogen activator"

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired